MedTrace Logo

A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis

NCT02238860 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-09-12

No results posted yet for this study

Summary

Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents have been claimed equivalent in treatment, there are no head to head trials available in the literature about there effectiveness in HBV Decompensated Cirrhosis. The investigators aimed to compare safety/efficacy and virological response in patients with HBV Decompensated Cirrhosis.

Conditions

  • Cirrhosis Due to Hepatitis B

Interventions

DRUG

Entacavir

Entacavir-0.5 mg ,OD,for

DRUG

Tenofovir

Tenofovir ,300 mg,OD,for 48 weeks

Sponsors & Collaborators

  • Asian Institute Of Medical Sciences

    lead OTHER

Principal Investigators

  • Mohammad sadik Memon, Fcps gastro · AIMS Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02238860 on ClinicalTrials.gov